Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease
Klatt et al. show that phagocytosis-shielded, BaEVRLess-pseudotyped retroviral vectors transduce human hematopoietic stem cells directly in vivo in mobilized humanized mice.